Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 25;6(11):3052–3061. doi: 10.1002/hep4.2064

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Cumulative incidence of hepatocellular carcinoma (HCC) over study period. (A) Cumulative incidence of HCC in subjects outside hepatitis B virus (HBV) treatment practice guidance with cirrhosis (115 of 226 [51%]) compared to subjects without cirrhosis who were outside HBV treatment practice guidance (18 of 1017 [2%]). (B) Cumulative incidence of HCC comparing subjects with compensated HBV/cirrhosis who were receiving nucleos(t)ide analogue (NA) therapy (112 of 348 [32%]) to subjects with compensated HBV/cirrhosis not receiving NAs therapy who were outside HBV treatment practice guidance (115 of 226 [51%]). (C) Cumulative incidence of HCC comparing all subjects with HBV/cirrhosis who were receiving NA therapy (158 of 412 [38%]) to all subjects with HBV/cirrhosis not receiving NAs therapy (143 of 485 [29%]). (D) Cumulative incidence of HCC comparing subjects with HBV/decompensated cirrhosis who were receiving NA therapy (96 of 114 [84%]) to subjects with HBV/decompensated cirrhosis not receiving NA therapy (26 of 230 [13%]). (E) Cumulative incidence of HCC in subjects with HBV and concomitant chronic liver disease (CLD) outside HBV treatment practice guidance (86 of 250 [34%]) compared to subjects with HBV and without concomitant CLD who were outside HBV treatment practice guidance (47 of 993 [5%]). (F) Cumulative incidence of HCC comparing all subjects with HBV who were receiving NA therapy at index presentation to subjects who received NAs therapy later on during the study period. *HBV_Rx indicates NA therapy.